Producing Wasp Venom Protein in Yeast for Allergy Treatment
Author Information
Author(s): Borodina Irina, Jensen Bettina M., Wagner Tim, Hachem Maher A., Søndergaard Ib, Poulsen Lars K.
Primary Institution: Technical University of Denmark
Hypothesis
Can enzymatically inactive variants of wasp venom phospholipase A1 be effectively expressed in Pichia pastoris for potential use in immunotherapy?
Conclusion
The study successfully expressed an enzymatically inactive wasp venom allergen that retains immunological activity, making it a candidate for recombinant immunotherapy.
Supporting Evidence
- The recombinant protein was shown to bind IgE antibodies from allergic patients.
- The H229A mutant of phospholipase A1 was secreted at higher yields than other variants.
- Histamine release assays confirmed the immunological activity of the recombinant protein.
Takeaway
Scientists made a wasp venom protein in yeast that doesn't cause allergic reactions but can still help treat allergies.
Methodology
The study involved cloning the phospholipase A1 gene, mutating it to create inactive variants, and expressing these in Pichia pastoris, followed by purification and immunological testing.
Limitations
The yield of the recombinant protein was low, and the expression of active phospholipase A1 negatively affected yeast growth.
Participant Demographics
Patients were selected based on high serum IgE reactivity to wasp venom and no cross-reactivity with honey bee venom.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website